GRAIL announced a partnership with Superpower, a health‑technology company that offers an all‑in‑one proactive health platform, to broaden the reach of its Galleri multi‑cancer early‑detection test. The collaboration will integrate Galleri into Superpower’s platform, which combines biomarker testing, AI‑powered analysis and access to clinical care teams, allowing patients to screen for signals from more than 50 cancer types before symptoms appear.
The partnership follows GRAIL’s strong financial performance in the fourth quarter of 2025, when total revenue grew 14% year‑over‑year to $43.6 million and U.S. Galleri revenue increased 31% to $41.3 million. Despite the revenue growth, the company reported a net loss of $99.2 million for the quarter, reflecting continued investment in its detection technology and the cost of scaling the Galleri test. GRAIL’s overall revenue for the full year 2025 was $147.17 million, a 17% increase from the prior year, underscoring the growing demand for early‑detection solutions.
Galleri has not yet received FDA clearance, but it holds a Breakthrough Device Designation and is CLIA‑certified and CAP‑accredited. The test’s ability to detect signals from over 50 cancer types addresses a critical gap in current screening standards, which cover only about five cancers. By partnering with Superpower, GRAIL aims to overcome the limited reach of its test and tap into a broader consumer base that already uses Superpower’s platform for routine biomarker screening.
Superpower’s EVP Enterprise, Prabhat Dhar, said the partnership “represents a fundamental shift, giving people the ability to screen for cancer signals before symptoms appear, when intervention can be most effective.” GRAIL’s President, Dr. Josh Ofman, added that “Superpower’s integrated approach combining comprehensive biomarker testing with multi‑cancer early detection represents the future of proactive health management.”
The collaboration is expected to accelerate GRAIL’s market penetration and generate additional revenue streams, while also providing Superpower with a cutting‑edge diagnostic tool that enhances its value proposition to consumers and healthcare providers. The partnership aligns with GRALI’s strategy to expand access to its Galleri test and capitalize on the growing demand for early‑detection technologies in a market that currently lacks comprehensive screening options.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.